|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00043329 |
|
Date of registration:
|
07/08/2002 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis
|
|
Scientific title:
|
Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis |
|
Date of first enrolment:
|
January 2002 |
|
Target sample size:
|
6 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00043329 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Retrospective
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Steven Porter, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
InterMune |
| | |
|
Key inclusion & exclusion criteria
|
- Male or female
- Diagnosis of severe, malignant osteopetrosis
- Currently receiving or planning to initiate therapy with Actimmune (Interferon
gamma-1b)
- Willing to attend follow-up appointments every 6 months following enrollment into the
study, if clinically indicated
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Osteopetrosis
|
|
Intervention(s)
|
|
Drug: Actimmune Registry
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|